CRIS Current Research Information System

DI FEDERICO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.583
NA - Nord America 3.083
EU - Europa 1.918
SA - Sud America 241
AF - Africa 204
Continente sconosciuto - Info sul continente non disponibili 204
OC - Oceania 4
Totale 10.237
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.960
VN - Vietnam 1.182
CN - Cina 1.117
SG - Singapore 1.083
IT - Italia 867
HK - Hong Kong 346
BD - Bangladesh 204
NL - Olanda 179
IN - India 174
DE - Germania 171
BR - Brasile 170
KR - Corea 163
SE - Svezia 122
GB - Regno Unito 100
FR - Francia 97
FI - Finlandia 91
CA - Canada 70
JP - Giappone 66
IE - Irlanda 63
CH - Svizzera 62
CI - Costa d'Avorio 62
RU - Federazione Russa 40
PH - Filippine 38
AR - Argentina 36
TH - Thailandia 36
TG - Togo 35
ID - Indonesia 31
SC - Seychelles 31
JO - Giordania 27
AT - Austria 26
NG - Nigeria 26
PL - Polonia 25
MX - Messico 22
ZA - Sudafrica 21
IQ - Iraq 19
TR - Turchia 17
ES - Italia 15
PK - Pakistan 14
TW - Taiwan 14
BG - Bulgaria 12
JM - Giamaica 12
BE - Belgio 9
CO - Colombia 9
LT - Lituania 8
UA - Ucraina 8
CL - Cile 7
EC - Ecuador 7
MY - Malesia 7
EG - Egitto 6
NI - Nicaragua 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
KE - Kenya 5
OM - Oman 5
SA - Arabia Saudita 5
VE - Venezuela 5
GR - Grecia 4
HN - Honduras 4
MA - Marocco 4
NP - Nepal 4
PY - Paraguay 4
AL - Albania 3
AZ - Azerbaigian 3
CR - Costa Rica 3
IL - Israele 3
KZ - Kazakistan 3
PT - Portogallo 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
HR - Croazia 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NZ - Nuova Zelanda 2
PE - Perù 2
SN - Senegal 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GM - Gambi 1
GP - Guadalupe 1
GT - Guatemala 1
IS - Islanda 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
ML - Mali 1
MM - Myanmar 1
MT - Malta 1
PR - Porto Rico 1
PS - Palestinian Territory 1
Totale 10.032
Salva come PNG Salva come JPEG
Città #
Singapore 774
Ashburn 417
Hefei 339
Hong Kong 322
San Jose 304
Ho Chi Minh City 297
Hanoi 267
Dallas 183
Santa Clara 164
Seoul 144
Beijing 143
Bologna 141
Council Bluffs 137
Chandler 116
Boardman 113
New York 112
Los Angeles 81
Milan 73
Abidjan 62
Dublin 62
Fairfield 61
Helsinki 61
Dong Ket 54
Buffalo 51
Rome 47
Tokyo 45
Bern 43
São Paulo 42
Lauterbourg 41
Seattle 39
Haiphong 38
Houston 38
Princeton 37
Southend 36
Lomé 35
Hyderabad 33
Munich 33
Turin 32
Bengaluru 31
Da Nang 30
Frankfurt am Main 30
Shanghai 30
Amman 25
Redondo Beach 25
Woodbridge 24
Cinquefrondi 22
Guangzhou 21
Hải Dương 21
Wilmington 21
Abeokuta 20
Biên Hòa 20
Modena 20
Falkenstein 19
Washington 19
Jakarta 17
Orem 17
Toronto 17
Warsaw 17
Amsterdam 16
London 16
Messina 16
Montreal 16
Phoenix 16
Tianjin 16
Turku 16
Visakhapatnam 16
Can Tho 15
Johannesburg 14
San Francisco 14
Stockholm 14
Atlanta 13
Cambridge 13
Chicago 13
Lappeenranta 13
Naples 13
The Dalles 13
Tongling 13
Florence 12
Quận Bình Thạnh 12
San Diego 12
Moncalieri 11
Sofia 11
Vienna 11
Xi'an 11
Brooklyn 10
Denver 10
Ha Long 10
Kingston 10
Ninh Bình 10
Nuremberg 10
Poplar 10
Bắc Giang 9
Mumbai 9
Quận Một 9
Zhengzhou 9
Bangkok 8
Boydton 8
Bắc Ninh 8
Columbus 8
Rimini 8
Totale 5.965
Salva come PNG Salva come JPEG
Nome #
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 298
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 290
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 278
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 248
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 238
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 231
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 222
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 211
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 201
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) 188
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 188
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 188
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 186
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 182
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter 182
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 180
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 179
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 176
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 172
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 169
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 167
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond 164
Hacking pancreatic cancer: Present and future of personalized medicine 163
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 160
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 157
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible? 151
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 150
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 149
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 145
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) 143
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 138
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 136
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients 135
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (Hcc) with orbital metastases: A case report 135
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report 133
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 130
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib 129
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 125
Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma 124
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 119
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 119
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 117
Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review 115
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis 112
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 111
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 111
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 109
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 107
Nivolumab: an investigational agent for the treatment of biliary tract cancer 106
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies 93
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review 92
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 92
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 92
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 91
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 89
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 86
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 86
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 86
Efficacy and Safety of TROP-2-Targeting Antibody–Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data 84
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 82
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database 77
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 76
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation 75
IMpower 132: Is the Second Exception to the Rule No Longer an Exception? 72
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 71
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 70
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 66
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC 64
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy 63
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 62
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% 62
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 62
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities 55
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects 53
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 47
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma 44
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 43
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer 37
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 36
Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis 32
Letter Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations 30
Totale 10.237
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.744
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.744
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022339 0 0 4 17 16 8 4 49 50 25 119 47
2022/2023734 38 77 35 42 102 57 29 51 141 40 50 72
2023/2024359 45 33 19 25 21 65 13 41 13 33 38 13
2024/20252.078 89 145 176 119 216 102 216 93 46 216 211 449
2025/20265.943 673 620 499 441 372 252 534 189 1.058 502 464 339
2026/2027520 212 242 66 0 0 0 0 0 0 0 0 0
Totale 10.237